title: Arachidonyltrifluoromethy ketone, a phospholipase A(2) antagonist, induces dispersal of both Golgi stack- and trans Golgi network-resident proteins throughout the cytoplasm.
abstract: Arachidonyltrifluoromethy ketone (AACOCF(3)), a phospholipase A(2) antagonist, reversibly induced dispersal of Golgi stack- and trans Golgi network (TGN)-resident proteins throughout the cytoplasm in NRK cells as followed by immunocytochemical staining of ManII and TGN38, respectively. The action of AACOCF(3) was partly blocked by other PLA(2) antagonists, suggesting it be not caused by a general inhibition of phospholipase A(2). AACOCF(3) neither dissociated beta-COP from membranes nor prevented brefeldin A-induced beta-COP release. Action of AACOCF(3) on the Golgi stack and TGN is different from that of brefeldin A and nordihydroguaiaretic acid. The most prominent difference is that the Golgi stack and TGN showed a similar sensitivity to AACOCF(3), while the TGN was dispersed more slowly than the Golgi stack in brefeldin A- or nordihydroguaiaretic acid-treated NRK cells. This novel action of AACOCF(3) may be used as pharmacological tool and give new insights into vesicle-mediated traffic and Golgi membrane dynamics.
authors.affiliation: Animal and Cellular Systems Laboratory, RIKEN (The Institute of Physical and Chemical Research), Hirosawa 2-1, Wako-shi, Saitama 351-0198, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kuroiwa
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.forename: M
authors.initials: M
authors.lastname: Tagaya
authors.forename: A
authors.initials: A
authors.lastname: Takatsuki
mesh_terms: D062365:Aminobenzoates / Q000494:pharmacology; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D020126:Brefeldin A / Q000494:pharmacology; D002460:Cell Line; D002723:Chlorobenzoates; D002934:Cinnamates / Q000494:pharmacology; D020756:Coatomer Protein / Q000187:drug effects / Q000378:metabolism; D003593:Cytoplasm / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006056:Golgi Apparatus / Q000187:drug effects* / Q000378:metabolism; D009637:Masoprocol / Q000494:pharmacology; D008565:Membrane Proteins / Q000187:drug effects* / Q000378:metabolism; D008856:Microscopy, Fluorescence; D009281:Naphthalenes / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism; D011753:Pyrones / Q000494:pharmacology; D013997:Time Factors; D062367:ortho-Aminobenzoates / Q000494:pharmacology
chemical_list: D062365:Aminobenzoates; D001095:Arachidonic Acids; D002723:Chlorobenzoates; D002934:Cinnamates; D020756:Coatomer Protein; D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D009281:Naphthalenes; D011753:Pyrones; D062367:ortho-Aminobenzoates; C081565:arachidonyltrifluoromethane; C085901:4-amylcinnamoylanthranilic acid; D020126:Brefeldin A; D009637:Masoprocol; C068314:6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; C060048:2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid; D010741:Phospholipases A